ScreenerHero

APMD Apnimed, Inc.

NAS · US · Healthcare · Biotechnology · apnimed.com
18.65USD-14.25%Mkt Cap: 776.41M $P/E: 2.58

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an ora…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.24BUSDP/E 29.3
REGN
Regeneron Pharmaceuticals, Inc.
$76.05BUSDP/E 18.3
MRNA
Moderna, Inc.
$74.84BUSD
ARGX
argenx SE
$56.77BUSDP/E 37.1
ARGX
argenx SE
$58.21BUSDP/E 35.5
UCB
UCB SA
$41.93BUSDP/E 17.9
RVMD
Revolution Medicines, Inc.
$42.84BUSD
ONC
BeOne Medicines AG
$41.27BUSDP/E 64.9
RPRX
Royalty Pharma plc
$32.61BUSDP/E 30.0
ALNY
Alnylam Pharmaceuticals, Inc.
$29.97BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.66BUSD
BNTX
BioNTech SE
$24.05BUSD
GMAB
Genmab A/S
$23.24BUSDP/E 29.8
GMAB
Genmab A/S
$22.23BUSDP/E 30.6
INSM
Insmed Incorporated
$22.98BUSD
INCY
Incyte Corporation
$22.85BUSDP/E 14.4
JAZZ
Jazz Pharmaceuticals plc
$15.02BUSDP/E 15.9
ASND
Ascendis Pharma A/S
$14.87BUSDP/E 17.3
EXEL
Exelixis, Inc.
$14.45BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$13.81BUSD

Key Statistics

Company
Market Cap776.41M USD
Enterprise Value929.90M USD
Revenue (TTM)115.12M USD
Gross Profit31.77M USD
Net Income (TTM)-932.00K USD
Revenue/Share21.25 USD
Last Price18.65 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees81
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)2.58
P/E (Forward)-4.69
PEG—
EV/EBITDA25.91
EV/Revenue8.08
P/S6.74
P/B-0.51
EPS (TTM)7.22
EPS (Forward)-3.98
52W Range
16.1213% of range35.29
52W High35.29 USD
52W Low16.12 USD
Profitability
Gross Margin82.60%
Oper. Margin-96.89%
EBITDA Margin31.18%
Profit Margin-2.42%
ROE0.25%
ROA-1.28%
Growth
Revenue Growth-29.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-77.83M USD
CapEx (TTM)—
FCF Margin—
FCF Yield—
Net Debt-92.46M USD
Net Debt/EBITDA-2.58
Balance Sheet
Debt/Equity-0.11
Current Ratio5.19
Quick Ratio4.88
Book Value/Sh-36.69 USD
Cash/Share4.15 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)50.33 USD
Upside (mean)+169.9%
Target Range41.00 USD – 60.00 USD
41.00+169.9% to mean60.00
# Analysts3
Ownership
Shares Out.41.63M
Float20.46M
Insiders35.61%
Institutions22.91%
Short Interest
Short Ratio2.7d
Short % Out.2.11%
Shares Short879.68K
Short (prev mo.)407.56K
Technical
SMA 5026.58 (-29.8%)
SMA 20026.58 (-29.8%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)562.21K
Avg Vol (10d)557.06K
Technical Indicators
RSI (14)34.1
MACD-1.7534
MACD Signal-1.3013
MACD Hist.-0.4521
BB Upper30.06 USD
BB Middle24.26 USD
BB Lower18.47 USD
BB Width47.80%
ATR (14)2.649 USD
Vol Ratio (20d)0.90x